ZYBERNO
Stock Report
Updated Aug 24, 2026

Brainsway Ltd. (BRSYF)

Healthcare • OTC

$16.84

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
26.0/100
POOR BUSINESS
Brainsway Ltd. (BRSYF) scores 26/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
MARGIN OF SAFETY
Is this stock cheap or expensive relative to what the business has historically generated for owners?
Margin of Safety unavailable — insufficient data for the owner-earnings DCF.
Is the market underestimating or overestimating what this business is capable of going forward?
-52.6%
Market Overestimates
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (4.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Brainsway Ltd. (BRSYF) stock report — Zyberno Score 26/100 (POOR BUSINESS). Full financial analysis on Zyberno.

According to Zyberno's DCF model, Brainsway Ltd. (BRSYF) shows a Brina Gap of -52.6%, which weakens the case: based on the company's ROIC (4.2%) and reinvestment rate (-63.3%), the business can fundamentally grow at -2.6% — but the current enterprise value implies the market expects 50.0%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:16.84
Market Cap:$659.55M

Valuation Multiples (2)

P/B Ratio:10.58x
Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:$590.21M
Ev Ebitda Ratio:287.77x
B. Profitability Assessment

Return Metrics (5)

Reinvestment Rate:-63.3%
Fundamental Growth Rate (g):-2.6%
Market-Implied Growth Rate:50.0%

Margin Analysis (1)

Ebitda Margin:5.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:5.19x
Quick Ratio:4.90x
Cash Ratio:4.52x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:0.00x

Coverage Ratios (2)

Interest Coverage Ratio:0.92x
Times Interest Earned:0.92

Capital Structure (4)

Working Capital:64,324,000.00
Cash And Cash Equivalents:69,345,000.00
Long Term Debt:$0.00
Net Debt:-$69.35M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$41.02M
Cost Of Revenue Ttm:$10.44M

Profitability Breakdown (2)

$30.58M$1.39M

Bottom Line Performance (3)

$2.92M
Income Before Tax:$0.00
Ebitda Ttm:2,051,000.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:$538.00K
Interest Expense:1,516,000.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:0.0%
Ebitda Margin:5.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$94.32M
Current Assets:$79.67M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:32,003,000.00
Current Liabilities:15,346,000.00
Long Term Debt:$0.00
Short Term Debt:$0.00

Equity & Capital (3)

Equity:$62.31M
Retained Earnings:$0.00
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:4,426,000.00
Accounts Payable:2,868,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

$10.30M$0.00

Investment Activities (1)

Investing Cash Flow:$30.31M

Financing Activities (3)

Financing Cash Flow:$18.26M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:$0.07

Revenue & Cash Per Share (2)

Sales Per Share Ttm:1.05
Operating Cash Flow Per Share:$0.26

Book Value & Capital (2)

Book Value Per Share:$1.59
Cash Per Share:1.77

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.43x
Working Capital Turnover Ttm:0.64x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:2.36x
Days Inventory Outstanding Ttm:154.81

Payables & Cash Cycle (2)

Days Payable Outstanding:100.32
Cash Conversion Cycle:-944.50
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:100.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (4)

Reinvestment Rate:-63.3%
Fundamental Growth Rate (g):-2.6%
Market-Implied Growth Rate:50.0%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:BRSYF
Company Name:Brainsway Ltd.
Sector:Healthcare
Industry:Medical Devices
Exchange:OTC
Country:Israel

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:39.17M
Shares Outstanding Basic:0
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-24 08:05:36 UTC
Data Timestamp:2026-08-24T08:05:36.765809
Scroll to Top